annual EBIT:
-$309.33M+$55.45M(+15.20%)Summary
- As of today (July 1, 2025), TVTX annual earnings before interest & taxes is -$309.33 million, with the most recent change of +$55.45 million (+15.20%) on December 31, 2024.
- During the last 3 years, TVTX annual EBIT has fallen by -$112.13 million (-56.86%).
- TVTX annual EBIT is now -373.22% below its all-time high of $113.22 million, reached on December 31, 2015.
Performance
TVTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
-$38.33M+$19.19M(+33.37%)Summary
- As of today (July 1, 2025), TVTX quarterly earnings before interest & taxes is -$38.33 million, with the most recent change of +$19.19 million (+33.37%) on March 31, 2025.
- Over the past year, TVTX quarterly EBIT has increased by +$94.64 million (+71.17%).
- TVTX quarterly EBIT is now -126.43% below its all-time high of $145.03 million, reached on September 30, 2015.
Performance
TVTX quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$214.69M+$94.64M(+30.59%)Summary
- As of today (July 1, 2025), TVTX TTM earnings before interest & taxes is -$214.69 million, with the most recent change of +$94.64 million (+30.59%) on March 31, 2025.
- Over the past year, TVTX TTM EBIT has increased by +$189.41 million (+46.87%).
- TVTX TTM EBIT is now -270.89% below its all-time high of $125.63 million, reached on September 30, 2015.
Performance
TVTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TVTX EBIT Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +15.2% | +71.2% | +46.9% |
3 y3 years | -56.9% | +47.8% | +3.5% |
5 y5 years | -142.4% | -188.6% | -131.5% |
TVTX EBIT Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -56.9% | +15.2% | at high | +71.2% | at high | +46.9% |
5 y | 5-year | -142.4% | +15.2% | -115.8% | +71.2% | -175.1% | +46.9% |
alltime | all time | -373.2% | +15.2% | -126.4% | +71.2% | -270.9% | +46.9% |
TVTX EBIT History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2025 | - | -$38.33M(-33.4%) | -$214.69M(-30.6%) |
Dec 2024 | -$309.33M(-15.2%) | -$57.52M(+10.5%) | -$309.33M(-8.4%) |
Sep 2024 | - | -$52.06M(-22.0%) | -$337.51M(-9.2%) |
Jun 2024 | - | -$66.78M(-49.8%) | -$371.86M(-8.0%) |
Mar 2024 | - | -$132.97M(+55.1%) | -$404.11M(+10.8%) |
Dec 2023 | -$364.78M(+13.9%) | -$85.71M(-0.8%) | -$364.77M(+0.8%) |
Sep 2023 | - | -$86.41M(-12.7%) | -$361.78M(+1.5%) |
Jun 2023 | - | -$99.02M(+5.8%) | -$356.46M(+10.9%) |
Mar 2023 | - | -$93.64M(+13.2%) | -$321.45M(+6.7%) |
Dec 2022 | -$320.14M(+62.3%) | -$82.72M(+2.0%) | -$301.21M(-0.5%) |
Sep 2022 | - | -$81.09M(+26.7%) | -$302.66M(+20.0%) |
Jun 2022 | - | -$64.01M(-12.8%) | -$252.27M(+13.4%) |
Mar 2022 | - | -$73.40M(-12.8%) | -$222.37M(+12.8%) |
Dec 2021 | -$197.20M(+16.2%) | -$84.16M(+174.2%) | -$197.20M(-14.4%) |
Sep 2021 | - | -$30.70M(-10.0%) | -$230.37M(+6.0%) |
Jun 2021 | - | -$34.11M(-29.3%) | -$217.43M(+6.2%) |
Mar 2021 | - | -$48.23M(-58.9%) | -$204.69M(+20.6%) |
Dec 2020 | -$169.74M(+33.0%) | -$117.33M(+560.7%) | -$169.74M(+117.5%) |
Sep 2020 | - | -$17.76M(-16.9%) | -$78.04M(-15.9%) |
Jun 2020 | - | -$21.37M(+60.9%) | -$92.75M(-11.8%) |
Mar 2020 | - | -$13.28M(-48.2%) | -$105.19M(-17.6%) |
Dec 2019 | -$127.62M(+38.6%) | -$25.63M(-21.1%) | -$127.62M(+22.1%) |
Sep 2019 | - | -$32.47M(-4.0%) | -$104.48M(-15.5%) |
Jun 2019 | - | -$33.81M(-5.3%) | -$123.59M(+11.5%) |
Mar 2019 | - | -$35.71M(+1332.5%) | -$110.88M(+20.3%) |
Dec 2018 | -$92.06M(+70.7%) | -$2.49M(-95.2%) | -$92.16M(-7.5%) |
Sep 2018 | - | -$51.57M(+144.3%) | -$99.60M(+50.0%) |
Jun 2018 | - | -$21.11M(+24.2%) | -$66.39M(+11.1%) |
Mar 2018 | - | -$16.99M(+71.1%) | -$59.78M(+7.1%) |
Dec 2017 | -$53.94M | -$9.93M(-45.9%) | -$55.81M(+3.3%) |
Sep 2017 | - | -$18.36M(+26.6%) | -$54.04M(-18.2%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2017 | - | -$14.50M(+11.3%) | -$66.03M(-8.5%) |
Mar 2017 | - | -$13.02M(+59.5%) | -$72.18M(+36.6%) |
Dec 2016 | -$52.85M(-146.7%) | -$8.16M(-73.1%) | -$52.85M(-7.8%) |
Sep 2016 | - | -$30.35M(+47.0%) | -$57.35M(-148.6%) |
Jun 2016 | - | -$20.65M(-427.3%) | $118.03M(+1.7%) |
Mar 2016 | - | $6.31M(-149.8%) | $116.09M(+2.5%) |
Dec 2015 | $113.22M(-241.9%) | -$12.66M(-108.7%) | $113.22M(-9.9%) |
Sep 2015 | - | $145.03M(-742.0%) | $125.63M(-461.5%) |
Jun 2015 | - | -$22.59M(-758.2%) | -$34.75M(+4829.6%) |
Mar 2015 | - | $3.43M(-1500.8%) | -$705.00K(-97.3%) |
Dec 2014 | -$79.81M(+222.2%) | -$245.00K(-98.4%) | -$26.20M(-12.9%) |
Sep 2014 | - | -$15.35M(-234.0%) | -$30.08M(+51.3%) |
Jun 2014 | - | $11.46M(-151.9%) | -$19.88M(-45.4%) |
Mar 2014 | - | -$22.06M(+434.8%) | -$36.44M(+124.0%) |
Dec 2013 | -$24.77M(-18.1%) | -$4.13M(-20.0%) | -$16.27M(+33.9%) |
Sep 2013 | - | -$5.15M(+1.1%) | -$12.14M(+73.7%) |
Jun 2013 | - | -$5.10M(+170.5%) | -$6.99M(+269.0%) |
Mar 2013 | - | -$1.89M(>+9900.0%) | -$1.89M(>+9900.0%) |
Dec 2012 | -$30.26M(>+9900.0%) | - | - |
Nov 2012 | - | -$3200.00(+6.7%) | -$13.00K(+1.6%) |
Aug 2012 | - | -$3000.00(0.0%) | -$12.80K(0.0%) |
May 2012 | - | -$3000.00(-21.1%) | -$12.80K(0.0%) |
Feb 2012 | - | -$3800.00(+26.7%) | -$12.80K(+1.6%) |
Feb 2012 | -$12.80K(+0.8%) | - | - |
Nov 2011 | - | -$3000.00(0.0%) | -$12.60K(-0.8%) |
Aug 2011 | - | -$3000.00(0.0%) | -$12.70K(-22.1%) |
May 2011 | - | -$3000.00(-16.7%) | -$16.30K(-18.1%) |
Feb 2011 | -$12.70K | -$3600.00(+16.1%) | -$19.90K(+22.1%) |
Nov 2010 | - | -$3100.00(-53.0%) | -$16.30K(+23.5%) |
Aug 2010 | - | -$6600.00(0.0%) | -$13.20K(+100.0%) |
May 2010 | - | -$6600.00 | -$6600.00 |
FAQ
- What is Travere Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Travere Therapeutics?
- What is Travere Therapeutics annual EBIT year-on-year change?
- What is Travere Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Travere Therapeutics?
- What is Travere Therapeutics quarterly EBIT year-on-year change?
- What is Travere Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Travere Therapeutics?
- What is Travere Therapeutics TTM EBIT year-on-year change?
What is Travere Therapeutics annual earnings before interest & taxes?
The current annual EBIT of TVTX is -$309.33M
What is the all time high annual EBIT for Travere Therapeutics?
Travere Therapeutics all-time high annual earnings before interest & taxes is $113.22M
What is Travere Therapeutics annual EBIT year-on-year change?
Over the past year, TVTX annual earnings before interest & taxes has changed by +$55.45M (+15.20%)
What is Travere Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of TVTX is -$38.33M
What is the all time high quarterly EBIT for Travere Therapeutics?
Travere Therapeutics all-time high quarterly earnings before interest & taxes is $145.03M
What is Travere Therapeutics quarterly EBIT year-on-year change?
Over the past year, TVTX quarterly earnings before interest & taxes has changed by +$94.64M (+71.17%)
What is Travere Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of TVTX is -$214.69M
What is the all time high TTM EBIT for Travere Therapeutics?
Travere Therapeutics all-time high TTM earnings before interest & taxes is $125.63M
What is Travere Therapeutics TTM EBIT year-on-year change?
Over the past year, TVTX TTM earnings before interest & taxes has changed by +$189.41M (+46.87%)